Pokroky v léčbě malobuněčného karcinomu plic

Česká verzia

Authors: D. Vrána
Authors place of work: Komplexní onkologické centrum, Nemocnice AGEL Nový Jičín a. s.
Published in the journal: Klin Onkol 2021; 34(Supplementum 1): 66-70
Category: Review
doi: https://doi.org/10.48095/ccko2021S66

Summary

Small cell lung cancer represents a disease with poor prognosis. Despite rapid progress in the fields of medical or radiation oncology, the treatment strategy of the small cell lung cancer has remained almost unchanged for over the last 30 years. Prophylactic cranial irradiation and irradiation of the primary lung tumor according to CREST clinical trial improved the median overall survival in months. Until the launch on immunotherapy, the systemic treatment didn’t make significant progress, unfortunately including targeted therapy. Immunotherapy significantly changed the treatment outcomes of the several tumor types and finally even the prognosis of small cell lung cancer. Clinical trials with atezolizumab and durvalumab have further moved forward the median overall survival by more than 2 months without significant increase in the treatment toxicity and worsening of the patient’s quality of life. In the combination with chemotherapy, atezolizumab and durvalumab represents a new gold standard in the treatment of small cell lung cancer.

Keywords:

lung cancer – immunotherapy – Chemotherapy

Zdroje

1. Slotman BJ, van Tinteren H, Praag JO et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015; 385 (9962): 36–42. doi: 10.1016/S0140-6736 (14) 61085-0. Erratum in: Lancet 2015; 385 (9962): 28.

2. Aupérin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341 (7): 476–484. doi: 10.1056/NEJM199908123410703.

3. Horn L, Mansfield AS, Szczęsna A et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379 (23): 2220–2229. doi: 10.1056/NEJMoa1809064.

4. Liu SV, Horn L, Mok T et al. 1781MO – IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer. [online]. Available from: https: //www.annalsofoncology.org/article/S0923-7534 (20) 41539-X/fulltext.

5. Paz-Ares L, Dvorkin M, Chen Y et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394 (10212): 1929–1939. doi: 10.1016/S0140-6736 (19) 32222-6.

6. Rudin CM, Awad MM, Navarro A et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: ran- domized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 2020; 38 (21): 2369–2379. doi: 10.1200/JCO.20. 00793.

7. Ready N, Farago AF, de Braud F et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol 2019; 14 (2): 237–244. doi: 10.1016/j.jtho.2018.10.003.

8. Antonia SJ, López-Martin JA, Bendell J et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 Jul; 17 (7): 883–895. doi: 10.1016/S1470-2045 (16) 30098-5. Erratum in: Lancet Oncol 2016; 17 (7): e270. Erratum in: Lancet Oncol 2019; 20 (2): e70.

9. Dennis M. BMS pulls small-cell lung cancer indication for Opdivo in US. [online]. Available from: https: //www.firstwordpharma.com/node/1787379?al=3a2ed4-70d11795b45b993bf2c50c85b591eb52%5E%7C%5EMTExMTE4NA%3D%3D%5E%7C%5ENQ%3D%3D&cp1=bmV3c2xldHRlcl9yZWdpb25faWQ9dG9wX 25ld3M=.

10. SPC Infinzi. [online]. Available from: https: //www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf

11. SPC Tecentriq. [online]. https: //www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_cs.pdf.

12. Mansfield AS, Kazarnowicz A, Karaseva N et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol 2020; 31 (2): 310–317. doi: 10.1016/j.annonc.2019.10.021.